TMO Stock Recent News

Market extremes often drive flawed narratives. Many investors get spooked by sell-offs or seduced by overvaluations, when real opportunity hides in discomfort. While today's market isn't euphoric, it's not cheap either. Risks remain, especially if growth stumbles. Yet long-term valuations may have structurally shifted. That's why I'm laser-focused on deep-value names. In this article, I highlight two standout stocks with unique long-term potential at compelling valuations.

TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.

KHC, CVX, and TMO stand out as some of the hardest-hit names held by big-name hedge funds.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today launched the spectral-enabled Invitrogen™ Attune™ Xenith™ Flow Cytometer, allowing immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples. By leveraging Thermo Fisher's legacy core acoustic focusing technology, this new solution offers improved time to results for scientists researching ce.

Thermo Fisher Scientific Inc. TMO is currently navigating a rare and telling phase in its journey through the Adhishthana Cycle. The stock is in its 18th Phase, simultaneously on both the weekly and monthly charts, a unique alignment that brings a powerful cyclical signal.

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase some of the technologies that have helped power precision oncology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Through poster presentations, abstracts, and an end-to-end presence across oncology diagnostics, clinical trials, and drug development, Thermo Fisher will demonstrate how its integrated solutions – from biomarker discovery to commercialization – a.

Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ TruNarc™ Delta and Tau Handheld Narcotics Analyzers* to help communities combat known and emerging narcotics and illicit substances. With touchless technology and an expanded chemical library, the user-friendly devices empower frontline law enforcement officials to identify more than 1,200 substances in the field, including stimulants, depressants, hallucinogen.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on July 15, 2025, to shareholders of record as of June 13, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier.